- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01487005
Cardiovascular Effects of Exposure to Ozone (MOSES)
Multicenter Ozone Study in Elderly Subjects
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
This multicenter study will investigate whether short-term exposure of elderly volunteers to ambient levels of O3 in a controlled exposure setting while intermittently exercising causes acute cardiovascular responses. The study is based on the suppositions that: 1) elderly people are a susceptible group for cardiovascular effects; and 2) effects are more likely with exercise.
The study will involve approximately 90 healthy volunteers aged ≥55 and ≤70 who meet strict criteria for inclusion. They will be exposed for 3 hours to clean air, 0.07 ppm O3 (near the current NAAQS), and 0.12 ppm O3 (a level measured in several locations in the US). A suite of cardiovascular and pulmonary endpoints will be measured on the day before the exposure and up to 22 hours after the exposures. The study is being conducted at three centers using a common protocol and common SOPs. Most the endpoints will be analyzed by core laboratories to reduce the variability in the results. A Data Coordination and Analysis Center will assemble all the data generated by the three centers and conduct the statistical analyses on the combined data sets.
The study has 3 main objectives:
- To determine the relationship of altered autonomic balance (measured as changes in heart rate and heart rate variability (HRV)), cardiac arrhythmia, and repolarization and ozone exposure.
- To identify instances of altered systemic vascular function [measured as brachial artery flow-mediated dilation (FMD)without and with nitroglycerin (NTG) when exposed to ozone.
- To identify pro-thrombotic vascular state (measured as increase in von Willebrand factor antigen in blood - primary endpoints) when exposed to ozone.
Additional objectives include:
- To identify any increase in micro particle-associated tissues factor (measured as number of particles and tissue factor activity) and platelet activation) in ozone exposure.
- To identify if markers of systemic oxidative stress and inflammation and any correlation with the cardiovascular effects and degree of airway injury (measured as CC16) and airway inflammatory effects (neutrophils and cytokines in induced sputum) in ozone exposure.
- To determine if cardiovascular effects in ozone exposure are correlated with airway inflammatory effects, but not lung function effects.
Tanulmány típusa
Beiratkozás (Várható)
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
San Francisco, California, Egyesült Államok, 94143
- Toborzás
- University of California at San Francisco
-
Kapcsolatba lépni:
- Hofer Wong
- Telefonszám: 415-206-8951
- E-mail: howong@sfghoem.ucsf.edu
-
Kutatásvezető:
- John Balmes, MD
-
-
Massachusetts
-
Watertown, Massachusetts, Egyesült Államok, 02472
- Aktív, nem toborzó
- New England Research Institutes, Inc.
-
-
New York
-
Rochester, New York, Egyesült Államok, 14642
- Toborzás
- University of Rochester
-
Kapcsolatba lépni:
- Erika Little
- Telefonszám: 585-275-4163
- E-mail: erika_little@urmc.rochester.edu
-
Kutatásvezető:
- Mark Frampton, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Egyesült Államok, 27599
- Toborzás
- University of North Carolina at Chapel Hill
-
Kapcsolatba lépni:
- Martha Almond
- Telefonszám: 919-966-0759
- E-mail: martha_almond@med.unc.edu
-
Kutatásvezető:
- Philip Bromberg, MD
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Leírás
Inclusion Criteria:
- males and females of all ethnic backgrounds.
- Normal spirometry (FEV1 and FVC >75% of predicted and FEV1/FVC >0.65).
- Ability to complete the exposure exercise regimen chosen to induce a ventilation rate of 15 to 17 L/min/m2 without exceeding 80% of predicted maximal heart rate.
- Normal baseline 12-lead resting ECG, and absence of significant ST depression while performing the 15-minute required level of exercise targeted for the exposure period.
- Subjects must be able to avoid certain medication supplements listed for 1 week before the exposure.
Exclusion Criteria:
- Non-English speaking.
- Including, but not limited to as ascertained by the physicians: Subjects with chronic cardiovascular (such as ischemic heart disease) or respiratory (such as asthma or COPD) disease; diabetes, or other organ or system dysfunction; cerebrovascular disease; active psychiatric disorders that would interfere with the subject's ability to understand and participate in the study. Subjects who have tested positive for a disease that affects the immune system (such as HIV, lymphoma, leukemia) or current drug or alcohol abuse (defined as having more than 3 drinks per day or being unable to abstain from alcohol for 3 days).
- Subjects with atopy or allergic rhinitis will not be excluded as long as they do not require regular treatment with antihistamines or systemic steroids.
- Ever-smokers (smoked tobacco or marijuana during the last five years, or with history of >10 pack year for tobacco or > 1 joint year for marijuana, or living with a smoker who smokes inside the house).
- Subject having plasma cotinine level > 3ng/mL.
- BMI >35 or <18 (35 is the official cut off for class 1 obesity).
- Hypertension (defined as blood pressure >140 systolic or >90diastolic) or on anti-hypertension medications other than diuretics.
- Pregnancy or nursing (breastfeeding).
- On the following medications: prednisone, statins, beta-blockers, anticoagulants, current hormonal therapy, tamoxifen. Subjects will not be asked to discontinue needed prescription medications for the purpose of this study. If any of these medications becomes necessary during the course of the study, the subjects will be excluded. Use of other medications will be considered on an individual basis.
- Subjects taking aspirin or PDE5 inhibitors must be willing to abstain from these medications during the week preceding each exposure.
- Occupational exposures (exposed to high levels of vapors, dust, gases, or fumes on an on-going basis)
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Időperspektívák: Leendő
Kohorszok és beavatkozások
Csoport / Kohorsz |
|---|
|
elderly subjects
Healthy
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change in endothelial function
Időkeret: Baseline (16 hours before exposure) and 4 hours after exposure
|
Brachail artey flow-mediated dilation and nitroglycerin-mediated dilation
|
Baseline (16 hours before exposure) and 4 hours after exposure
|
|
Change in heart rate variability
Időkeret: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
measured with Holter monitor
|
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
|
Change in prothrombotic vascular state
Időkeret: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
Peripheral blood samples will be taken and stored as plasma for measurement of von Willenbrand Factor antigen
|
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
|
Change in cardiac repolarization
Időkeret: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
from Holter monitor
|
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change in markers of systemic inflammation
Időkeret: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
Peripheral blood samples will be taken and stored as plasma for measurements of inflammatory markers
|
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
|
Change in lung function
Időkeret: Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
|
Spirometry
|
Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
|
|
Lung inflammation
Időkeret: 22 hours after exposure
|
A sputum sample will be obtained and stored for measurement of inflammatory mediators
|
22 hours after exposure
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Kutatásvezető: Anne Stoddard, PhD, HealthCore-NERI
Publikációk és hasznos linkek
Általános kiadványok
- Rich DQ, Thurston SW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Alexis NE, Ganz P, Zareba W, Thevenet-Morrison K, Koutrakis P, Frampton MW. Do Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function? Ann Am Thorac Soc. 2020 May;17(5):563-572. doi: 10.1513/AnnalsATS.201908-597OC.
- Arjomandi M, Balmes JR, Frampton MW, Bromberg P, Rich DQ, Stark P, Alexis NE, Costantini M, Hollenbeck-Pringle D, Dagincourt N, Hazucha MJ. Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in Older Subjects). Am J Respir Crit Care Med. 2018 May 15;197(10):1319-1327. doi: 10.1164/rccm.201708-1613OC.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Várható)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
Egyéb vizsgálati azonosító számok
- 10-01-4
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .